About Quince Therapeutics
Quince Therapeutics is a company based in San Francisco (United States) founded in 2012.. Quince Therapeutics has raised $108.09 million across 6 funding rounds from investors including Verily, Takeda Pharmaceuticals and EPIQ. The company has 36 employees as of December 31, 2024. Quince Therapeutics has completed 1 acquisition, including EryDel. Quince Therapeutics offers products and services including eDSP and AIDE Technology. Quince Therapeutics operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
- Headquarter San Francisco, United States
- Employees 36 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Quince Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-56.83 M-81.07as on Dec 31, 2024
-
EBITDA
$-35.98 M-47.96as on Dec 31, 2024
-
Total Equity Funding
$108.09 M (USD)
in 6 rounds
-
Latest Funding Round
$125 M (USD), Post-IPO
Feb 05, 2020
-
Investors
Verily
& 12 more
-
Employee Count
36
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Quince Therapeutics
Quince Therapeutics is a publicly listed company on the NASDAQ with ticker symbol QNCX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Quince Therapeutics
Quince Therapeutics offers a comprehensive portfolio of products and services, including eDSP and AIDE Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for Ataxia-Telangiectasia using encapsulated corticosteroids.
Platform for encapsulating drugs into red blood cells.
Unlock access to complete
Unlock access to complete
Funding Insights of Quince Therapeutics
Quince Therapeutics has successfully raised a total of $108.09M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $125.0M
-
First Round
First Round
(11 Jun 2014)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2020 | Amount | Post-IPO - Quince Therapeutics | Valuation |
investors |
|
| May, 2018 | Amount | Series B - Quince Therapeutics | Valuation |
investors |
|
| Feb, 2017 | Amount | Series A - Quince Therapeutics | Valuation | Takeda Ventures , Breakout Labs |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Quince Therapeutics
Quince Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Verily, Takeda Pharmaceuticals and EPIQ. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage science-driven companies are supported through venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Quince Therapeutics
Quince Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EryDel. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Erythrocyte encapsulation systems for drug delivery are developed.
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Quince Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Quince Therapeutics Comparisons
Competitors of Quince Therapeutics
Quince Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for bone regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| domain | founded_year | HQ Location |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Advanced cell separation technologies are developed for regenerative cell preparation.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Quince Therapeutics
Frequently Asked Questions about Quince Therapeutics
When was Quince Therapeutics founded?
Quince Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Where is Quince Therapeutics located?
Quince Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Quince Therapeutics?
Dirk Thye is the current CEO of Quince Therapeutics.
Is Quince Therapeutics a funded company?
Quince Therapeutics is a funded company, having raised a total of $108.09M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7.6M, raised on Jun 11, 2014.
How many employees does Quince Therapeutics have?
As of Dec 31, 2024, the latest employee count at Quince Therapeutics is 36.
What does Quince Therapeutics do?
Quince Therapeutics was founded in 2012 and is based in San Francisco, United States. Focus is placed on developing therapeutics within the biotechnology sector for orthopedic diseases. Operations center on innovative candidates, including the lead product NOV004, an anabolic peptide engineered to target bone fracture sites for enhanced concentration. Applications extend to spinal fusion procedures and treatment of osteogenesis imperfecta.
Who are the top competitors of Quince Therapeutics?
Quince Therapeutics's top competitors include Horizon Therapeutics, ZetaGen and Angitia.
What products or services does Quince Therapeutics offer?
Quince Therapeutics offers eDSP and AIDE Technology.
Is Quince Therapeutics publicly traded?
Yes, Quince Therapeutics is publicly traded on NASDAQ under the ticker symbol QNCX.
How many acquisitions has Quince Therapeutics made?
Quince Therapeutics has made 1 acquisition, including EryDel.
Who are Quince Therapeutics's investors?
Quince Therapeutics has 13 investors. Key investors include Verily, Takeda Pharmaceuticals, EPIQ, Takeda Ventures, and Breakout Ventures.
What is Quince Therapeutics's ticker symbol?
The ticker symbol of Quince Therapeutics is QNCX on NASDAQ.